Target/therapies for chronic recurrent erythema nodosum leprosum

A Type 2 lepra reaction or erythema nodosum leprosum is an anticipated complication in the lepromatous spectrum of leprosy cases. It is an example of an immune complex-mediated complement activated disease (Type III hypersensitivity reaction). Hence, we tried to target the inflammatory mediators and...

Descripción completa

Detalles Bibliográficos
Autores principales: Thangaraju, Pugazhenthan, Varthya, Shoban Babu, Venkatesan, Sajitha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Potential Pharmacological Targets
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446680/
https://www.ncbi.nlm.nih.gov/pubmed/32874007
http://dx.doi.org/10.4103/ijp.IJP_788_19
_version_ 1783574168357306368
author Thangaraju, Pugazhenthan
Varthya, Shoban Babu
Venkatesan, Sajitha
author_facet Thangaraju, Pugazhenthan
Varthya, Shoban Babu
Venkatesan, Sajitha
author_sort Thangaraju, Pugazhenthan
collection PubMed
description A Type 2 lepra reaction or erythema nodosum leprosum is an anticipated complication in the lepromatous spectrum of leprosy cases. It is an example of an immune complex-mediated complement activated disease (Type III hypersensitivity reaction). Hence, we tried to target the inflammatory mediators and the mental stressors for the possible management strategies.
format Online
Article
Text
id pubmed-7446680
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-74466802020-08-31 Target/therapies for chronic recurrent erythema nodosum leprosum Thangaraju, Pugazhenthan Varthya, Shoban Babu Venkatesan, Sajitha Indian J Pharmacol Potential Pharmacological Targets A Type 2 lepra reaction or erythema nodosum leprosum is an anticipated complication in the lepromatous spectrum of leprosy cases. It is an example of an immune complex-mediated complement activated disease (Type III hypersensitivity reaction). Hence, we tried to target the inflammatory mediators and the mental stressors for the possible management strategies. Wolters Kluwer - Medknow 2020 2020-08-04 /pmc/articles/PMC7446680/ /pubmed/32874007 http://dx.doi.org/10.4103/ijp.IJP_788_19 Text en Copyright: © 2020 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Potential Pharmacological Targets
Thangaraju, Pugazhenthan
Varthya, Shoban Babu
Venkatesan, Sajitha
Target/therapies for chronic recurrent erythema nodosum leprosum
title Target/therapies for chronic recurrent erythema nodosum leprosum
title_full Target/therapies for chronic recurrent erythema nodosum leprosum
title_fullStr Target/therapies for chronic recurrent erythema nodosum leprosum
title_full_unstemmed Target/therapies for chronic recurrent erythema nodosum leprosum
title_short Target/therapies for chronic recurrent erythema nodosum leprosum
title_sort target/therapies for chronic recurrent erythema nodosum leprosum
topic Potential Pharmacological Targets
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446680/
https://www.ncbi.nlm.nih.gov/pubmed/32874007
http://dx.doi.org/10.4103/ijp.IJP_788_19
work_keys_str_mv AT thangarajupugazhenthan targettherapiesforchronicrecurrenterythemanodosumleprosum
AT varthyashobanbabu targettherapiesforchronicrecurrenterythemanodosumleprosum
AT venkatesansajitha targettherapiesforchronicrecurrenterythemanodosumleprosum

Ejemplares similares